Tirzepatide (LY3298176, Mounjaro) is the first dual GIP and GLP-1 RAs for the treatment of T2DM, obesity, and nonalcoholic steatohepatitis [14]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.